stoxline Quote Chart Rank Option Currency Glossary
Cocrystal Pharma, Inc. (COCP)
1.45  -0.08 (-5.23%)    04-12 16:00
Open: 1.5568
High: 1.5568
Volume: 13,286
Pre. Close: 1.53
Low: 1.44
Market Cap: 15(M)
Technical analysis
2024-04-12 4:48:26 PM
Short term     
Mid term     
Targets 6-month :  1.88 1-year :  2.03
Resists First :  1.61 Second :  1.74
Pivot price 1.5
Supports First :  1.39 Second :  1.16
MAs MA(5) :  1.53 MA(20) :  1.5
MA(100) :  1.61 MA(250) :  2.04
MACD MACD :  0 Signal :  0
%K %D K(14,3) :  37.2 D(3) :  44.1
RSI RSI(14): 45
52-week High :  3.28 Low :  1.33
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ COCP ] has closed above bottom band by 24.1%. Bollinger Bands are 18.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 1.56 - 1.57 1.57 - 1.58
Low: 1.42 - 1.43 1.43 - 1.44
Close: 1.43 - 1.45 1.45 - 1.47
Company Description

Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that is in preclinical development trials for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections; and drug discovery collaboration with HitGen and InterX Inc. The company is headquartered in Bothell, Washington.

Headline News

Mon, 08 Apr 2024
Q1 2024 EPS Estimates for Cocrystal Pharma, Inc. (NASDAQ:COCP) Boosted by HC Wainwright - Defense World

Sat, 06 Apr 2024
HC Wainwright Comments on Cocrystal Pharma, Inc.'s Q1 2025 Earnings (NASDAQ:COCP) - Defense World

Fri, 05 Apr 2024
HC Wainwright Reaffirms Buy Rating for Cocrystal Pharma (NASDAQ:COCP) - Defense World

Mon, 01 Apr 2024
Do Traders Think Cocrystal Pharma Inc (COCP) Can Turn Around Monday? - InvestorsObserver

Sun, 31 Mar 2024
Cocrystal Pharma (NASDAQ:COCP) Announces Quarterly Earnings Results, Beats Estimates By $0.13 EPS - Defense World

Tue, 19 Mar 2024
Cocrystal Pharma Advances Influenza A Treatment Development - - TipRanks

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 10 (M)
Shares Float 7 (M)
Held by Insiders 30 (%)
Held by Institutions 6.7 (%)
Shares Short 4 (K)
Shares Short P.Month 3 (K)
Stock Financials
EPS -1.98
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 3.01
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -32 %
Return on Equity (ttm) -48.4 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -1.95
Qtrly Earnings Growth 0 %
Operating Cash Flow -16 (M)
Levered Free Cash Flow -11 (M)
Stock Valuations
PE Ratio -0.74
PEG Ratio 0
Price to Book value 0.48
Price to Sales 0
Price to Cash Flow -0.91
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android